Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 170 posts found.

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

April 2, 2024
Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …

News

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023
Research and Development Genentech, Oncology, breast cancer, oncology

Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …

News

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

November 17, 2023
Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …

News

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …

News

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023
Medical Communications European Commission, Oncology, Orserdu, breast cancer

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …

News
national-cancer-institute-kmvohcb-w5g-unsplash_1

FDA approves Pfizer’s HRR mCRPC drug

June 21, 2023
Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer

US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

AstraZeneca’s breast cancer drug given Priority Review by FDA

June 13, 2023
Business Services AstraZeneca, FDA, Oncology, breast cancer

UK-based pharmaceutical company AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application …

News

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

May 23, 2023
Research and Development FDA, Lumicell, Oncology, breast cancer, oncology

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New …

News
laboratory-testing-az

Polyphor’s future in question after co-primary endpoint in breast cancer study missed

June 28, 2021
Sales and Marketing Primary Endpoint, breast cancer

Swiss biopharmaceutical company, Polyphor, has announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin …

News

Medical cannabis formulation kills breast cancer cells in trial

June 28, 2021
Sales and Marketing breast cancer, medical cannabis, oncology

UK-based pharma company, Apollon Formularies, have announced that their medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) …

News

Novartis report longest median OS in breast cancer study

June 3, 2021
Novartis, breast cancer, trials

Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …

News
credit_-_crevis_shutterstock_340710245_720

Enhertu now available via Cancer Drugs Fund following NICE decision

April 20, 2021
Manufacturing and Production AstraZeneca, breast cancer, oncology

AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …

News
takeda_usa_pharmaceuticals_u

Takeda’s breast cancer treatment approved in Scotland

February 9, 2021
Manufacturing and Production Takeda, breast cancer

The Scottish Medicines Consortium has accepted Takeda’s PROSTAP 3 DCS (leuprorelin acetate) treatment for use in patients with early and …

News

Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer

December 9, 2020
Research and Development Kisqali, Novartis, breast cancer

Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024